Cabaletta Bio, Inc. · NASDAQ:CABA
Cabaletta Bio — Investor Presentation (March 2023)
21 slides from Cabaletta Bio's investor presentation, Mar 16, 2023
Slide 1: Corporate Presentation March 2023
Corporate Presentation march 2023 Exhibit 99.2
Slide 2: Disclaimer
Disclaimer The following presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document or material distributed at or in connection wi
Slide 3: Develop and launch the first curative targeted cellular therapies for autoimmune diseases
Develop and launch the first curative targeted cellular therapies for patients with autoimmune diseases
Slide 4: Experienced team uniquely positioned to efficiently advance CABA-201 in autoimmune diseases
Experienced team uniquely positioned to efficiently advance CABA-201 in a range of autoimmune diseases Cabaletta®: Pursuing cures for a broad range of autoimmune diseases CAART – Chimeric AutoAntibody Receptor T cells; CARTA – Chimeric Antigen Receptor T cells for Autoimmunity; IND – Investigational
Slide 5: One CABA platform, two strategies to address autoimmune diseases
One CABA™ platform, two strategies to address autoimmune diseases Complementary strategies to optimize clinical outcomes using cellular therapies in autoimmune diseases Mackensen, Andreas, et al. "Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus." Nature Medicine (2022): 1-9.
Slide 6: Biologic opportunity for cure or treatment may be possible in dozens of autoimmune diseases
Biologic opportunity for cure or treatment may be possible in dozens of autoimmune diseases* CABA™ platform may apply across a range of autoimmune diseases Pemphigus Vulgaris1,2,3 Pemphigus Foliaceus1,2,3 Epidermolysis Bullosa Acquisita3 Bullous Pemphigoid1,2,3 Lupus Nephritis3,4 Membranous Nephropa
Slide 7: Pipeline targeting autoimmune diseases where cure is possible
Pipeline targeting autoimmune diseases where cure is possible Additional CAART disease targets in discovery stage include two undisclosed indications. We have discontinued work on FVIII-CAART due to the prioritization of other product candidates. CABA™ Platform Indication Program Discovery Preclinic
Slide 8: Chimeric Antigen Receptor T Cells for Autoimmunity CABA-201
Chimeric Antigen Receptor T Cells for Autoimmunity CABA-201
Slide 9: Academic data: immune system reset in SLE and myositis patients
SLE – Systemic lupus erythematosus; ASyS – Anti-synthetase syndrome; scFv – Single chain variable fragment; SLEDAI-2K – Systemic Lupus Erythematosus Disease Activity Index 2000; CRS – Cytokine release syndrome; ICANS – Immune effector cell-associated neurotoxicity syndrome; Anti-dsDNA Abs – Anti-dou
Slide 10: CABA-201: CD19-targeting CAR T therapy for autoimmune diseases
Cabaletta’s CD19 binder with similar in vitro & in vivo activity to FMC631 (binder used in academic studies2,3) CABA-201: CD19-targeting CAR T therapy for autoimmune diseases SLE – Systemic lupus erythematosus; IIT – Investigator-initiated trial; Flu/Cy – Fludarabine/Cyclophosphamide; CRS – Cytokine
Slide 11: Differentiated asset, exclusive translational insights and track record of timely CAART clinical implementation
Differentiated asset, exclusive translational insights & track record of timely CAART clinical implementation Accelerating development of CABA-201 for autoimmune diseases SLE – Systemic lupus erythematosus Mackensen, Andreas, et al. "Anti-CD19 CAR T cell therapy for refractory systemic lupus erythem
Slide 12: Chimeric AutoAntibody Receptor T Cells DSG3-CAART & MuSK-CAART
Chimeric AutoAntibody Receptor T Cells DSG3-CAART & MuSK-CAART
Slide 13: Current treatments require broad immunosuppression with safety risks and transient efficacy
Current treatments require broad immunosuppression associated with safety risks and transient efficacy Overview of pemphigus vulgaris & current treatment landscape Image credit: D@nderm. http://www.vgrd.org/archive/cases/2004/pv/DSCN4996%20copy.JPG Joly, Pascal, et al. "First-line rituximab combined
Slide 14: Monotherapy DSG3-CAART demonstrates favorable tolerability, but persistence plateaus
Monotherapy DSG3-CAART demonstrates favorable tolerability to date, but persistence plateaus Ongoing DesCAARTes™ study in patients with mucosal PV FDA has requested, and the Company has agreed, that we will share data from part A to inform a discussion on the optimal design of part C. According to F
Slide 15: Combination strategy to enhance cytokine and/or diminish autoantibody effects on CAART activity
Combination strategy designed to enhance cytokine and/or diminish autoantibody effects on CAART activity Combination sub-study prioritized to increase CAART exposure Amagai, Masayuki, et al. "A randomized double-blind trial of intravenous immunoglobulin for pemphigus." Journal of the American Academ
Slide 16: Strategy for first-in-human MuSK-CAART trial informed by DesCAARTes study
Strategy for first-in-human trial informed by learnings from DesCAARTes™ study High unmet need in MuSK myasthenia gravis MusCAARTes™ study of MuSK-CAART Ongoing open-label study to determine the maximum tolerated dose & to evaluate safety of MuSK-CAART Part Cohort Subjects A – Monotherapy Dose Escal
Slide 17: Corporate Summary
Corporate Summary Cabaletta Bio’
Slide 18: Manufacturing strategy: three-stage approach for efficient capital allocation
Three-stage approach allows for efficient allocation of capital while leveraging experienced partners Manufacturing strategy CDMOs shown are currently contracted for select CAART product candidates. Stage 3: Commercialization & Scale-Up Data-gated, staged investment Stage 1: Penn Stage 2: CDMOs & CA
Slide 19: Cabaletta Bio leadership
BOARD OF DIRECTORS Cabaletta Bio leadership LEADERSHIP TEAM Anup Marda Chief Financial Officer Arun Das, M.D. Chief Business Officer David J. Chang, M.D., M.P.H., FACR Chief Medical Officer Martha O’Connor Chief HR Officer Michael Gerard General Counsel Steven Nichtberger, M.D. President, CEO & Chai
Slide 20: Multiple potential clinical catalysts anticipated in next 18 months
Multiple potential clinical catalysts anticipated in next 12-18 months1 Assumes no dose-limiting toxicities are observed in any cohort and uninterrupted enrollment occur in the trials. Subject to and pending clearance of CABA-201 IND by the FDA. Cash runway into 1Q25 CABA-201 4-1BB CD19-CAR T Expect
Slide 21: Corporate Presentation MARCH 2023
Corporate Presentation MARCH 2023